Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01741883
Other study ID # DFG NE 1635/2-1
Secondary ID
Status Active, not recruiting
Phase N/A
First received December 4, 2012
Last updated September 24, 2017
Start date November 2012
Est. completion date August 2020

Study information

Verified date September 2017
Source Philipps University Marburg Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate a side effect prevention training (SEPT) that optimizes patients' response expectations before the start of adjuvant endocrine treatment (AET) to prevent nocebo side effects and enhance quality of life during longer term drug intake.


Description:

The majority of breast cancer patients discontinue today's standard adjuvant treatment (endocrine therapy) due to side effects and reduced quality of life. Thereby, most side effects are unspecific, thus, not related to the specific pharmacological action of the drug, but to the individual treatment context and patients´ expectations (nocebo effects). The aim of this study is to evaluate a side effect prevention training (SEPT) that optimizes patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during longer term drug intake. Using a randomized trial, we will study the time course of response expectations and side effects in breast cancer patients receiving either SEPT, standard medical care or an attention-control intervention ("supportive therapy") before the start of adjuvant endocrine therapy. We will analyze the effects of changing pre-treatment expectations on cancer-treatment related side effects, quality of life and adherence 3 and 6 months after the start of endocrine therapy. Moderator analyses will be used to determine predictors of non-specific medication side effects and patients that are at high risk of experiencing them. Furthermore, we will explore the mediating influence of coping behaviours, thereby providing insights into pathways of clinical nocebo effects. The study findings promise significant advances in the clinical application of nocebo research with strong implications for clinical and research practice.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 165
Est. completion date August 2020
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Women with estrogen receptor positive breast cancer scheduled to start first-line adjuvant endocrine therapy with Tamoxifen (+/- GnRH) or a third generation Aromatase inhibitor at the Breast Cancer Centre

- Sufficient knowledge of German language and ability to give informed consent

- Age of 18 and more

Exclusion Criteria:

- Presence of a serious comorbid psychiatric condition (schizophrenia or addiction, severe depression or anxiety)

- Presence of a life threatening comorbid medical condition

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Side effect prevention training (SEPT)
SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
Attention Control group (ACG)
Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).

Locations

Country Name City State
Germany University Medical Center Hamburg-Eppendorf Hamburg

Sponsors (3)

Lead Sponsor Collaborator
Philipps University Marburg Medical Center Universitätsklinikum Hamburg-Eppendorf, University of Hamburg

Country where clinical trial is conducted

Germany, 

References & Publications (1)

von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer. 2013 Sep 18;13:426. doi: 10.1186/1471-2407-13-426. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Side Effects (General Assessment of Side Effects, GASE) Side Effects 3 and 6 months after the start of adjuvant endocrine therapy, controlled for baseline symptoms, staging, age, medication Baseline, 3 and 6 months after the start of adjuvant endocrine therapy (AET)
Secondary Change in Patients Expectations (General Assessment of Side Effects-Expect/Cope, Gase-Expect/Cope; Brief Illness Perceptions Questionnaire, B-IPQ; Beliefs about medicine questionnaire, BMQ-D) Change in patients expectations from baseline/pre-intervention (expected average 2 weeks after surgery) to post-intervention (expected average 5 weeks after surgery) and prospective expectations 3 and 6 months after the start of adjuvant endocrine therapy Baseline and 5 weeks after surgery, before start of adjuvant endocrine therapy
Secondary Change in Anxiety and Depression (Hospital Anxiety and Depression Scale, HADS-D) Change in anxiety and depression from baseline to 5 weeks after surgery to 3 months after the start of AET to 6 months after the start of AET Baseline, 5 weeks after surgery, 3 months after the start of adjuvant endocrine therapy (AET) and 6 months after the start of AET
Secondary Change in Fear of Progression (Fear of Progression Questionnaire-Short Form, FoP-Q-SF) Change in Fear of Progression from baseline to 5 weeks after surgery to 3 months after the start of AET to 6 months after the start of AET Baseline, 5 weeks after surgery, 3 months after the start of adjuvant endocrine therapy (AET) and 6 months after the start of AET
Secondary Change in Adherence Intention and Adherence (Medication Adherence Report Scale, MARS-D) Change in Adherence Intention and Adherence from baseline to 5 weeks after surgery to 3 months after the start of AET to 6 months after the start of AET Baseline, 5 weeks after surgery, 3 months after the start of adjuvant endocrine therapy (AET) and 6 months after the start of AET
Secondary Change in Quality of Life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire with breast module, EORTC QLQ-C30 and QLQ-BR23) Change in Quality of Life from baseline to 3 months after the start of adjuvant endocrine therapy to 6 months after the start of adjuvant endocrine therapy Baseline, 3 and 6 months after the start of adjuvant endocrine therapy (AET)
Secondary Change in Coping with Side Effects (General Assessment of Side Effects-Cope, GASE-Cope) Change in coping with Side Effects from 3 months after the start of adjuvant endocrine therapy to 6 months after the start of adjuvant endocrine therapy 3 and 6 months after the start of adjuvant endocrine therapy (AET)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Completed NCT05000502 - Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations N/A
Not yet recruiting NCT04863833 - Tomosymthesis for Breast Mass Lesion Characterization
Withdrawn NCT06145399 - A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer Early Phase 1
Suspended NCT01320488 - Breast Cancer in Young Women: Is it Different? N/A
Recruiting NCT02089854 - Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Phase 4
Recruiting NCT06144164 - A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer Phase 3
Recruiting NCT06331793 - Pulsed Electromagnetic Fields for Analgesia Post Mastectomy N/A
Recruiting NCT05439499 - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. Phase 3
Terminated NCT03836872 - Acupuncture for Joint Symptoms in Patients With Breast Cancer N/A
Recruiting NCT06332976 - PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Completed NCT01671319 - Dose Dense TC + Pegfilgrastim Support for Breast Cancer Phase 2
Not yet recruiting NCT06092892 - IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases Phase 2
Recruiting NCT05586256 - Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
Not yet recruiting NCT03153631 - Female Sexual Dysfunction in Breast Cancer Patients N/A
Active, not recruiting NCT03059875 - Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter) N/A
Active, not recruiting NCT02088710 - Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer N/A
Terminated NCT01083641 - Estrogen for Triple Negative Breast Cancer Phase 2
Recruiting NCT05374161 - An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain N/A
Recruiting NCT05438810 - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. Phase 3